Development of silkworm-derived human fibrinogen as a pharmaceutical ingredient
First written in FY2016. 5 of 7 entries say "Restated". Latest entry: FY2018.
No other company in this theme has enough history to compare yet.
- FY2018DroppedAnnual report
「Because production of the target protein, fibrinogen, failed to reach the volume required to meet the target cost for use as a drug, we have regrettably decided to abandon efforts toward commercial production.」
Regarding silkworm-derived human-type fibrinogen with Astellas Pharma Inc., the company failed to achieve a production volume sufficient to meet the target cost and abandoned efforts toward commercial production. - FY2018-Q1RestatedAnnual report
「In joint research and development with Astellas Pharma Inc., we aim to increase the production yield of human-type fibrinogen produced from genetically modified silkworm cocoons and establish a stable method for large-scale rearing using large-scale rearing facilities.」
The company continues joint research with Astellas Pharma Inc. and aims to increase production and achieve large-scale rearing in preparation for commercializing silkworm-derived human-type fibrinogen as a pharmaceutical raw material. - FY2017RestatedAnnual report
「We are currently actively pursuing joint research with Astellas Pharma Inc. aimed at commercializing human fibrinogen as a pharmaceutical raw material.」
The company continues joint research on human-type fibrinogen with Astellas Pharma Inc. - FY2017-Q3RestatedAnnual report
「Joint research with Astellas Pharma Inc. aimed at commercializing pharmaceuticals using human-type fibrinogen produced by genetically modified silkworms as the raw material」
The company continues joint research aimed at commercializing pharmaceuticals using human-type fibrinogen derived from genetically modified silkworms as the raw material. - FY2017-Q2RestatedAnnual report
「Joint research with Astellas Pharma Inc. aimed at commercializing pharmaceuticals using human-type fibrinogen produced by genetically modified silkworms as the raw material」
The company continues joint research with Astellas Pharma Inc. and aims to commercialize pharmaceuticals using human-type fibrinogen derived from genetically modified silkworms as the raw material. - FY2017-Q1RestatedAnnual report
「In this business, we are conducting joint research with Astellas Pharma Inc. aimed at commercializing pharmaceuticals using human-type fibrinogen produced by genetically modified silkworms as the raw material,」
The company continues joint research with Astellas Pharma Inc. and aims to commercialize human-type fibrinogen derived from genetically modified silkworms as a pharmaceutical raw material and as a product. - FY2016First statedAnnual report
「We are currently actively pursuing joint research with Astellas Pharma Inc. aimed at commercializing human fibrinogen as a pharmaceutical raw material.」
Through joint research with Astellas Pharma Inc., the company aims to commercialize recombinant human fibrinogen derived from silkworms as a pharmaceutical raw material.